NCT03263442View on ClinicalTrials.gov

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

March 2, 2020

Study Completion Date

August 10, 2020

Conditions
Hematopoietic Stem Cell TransplantationDeliriumThiamine Deficiency
Interventions
DRUG

Thiamine

200 mg IV three times daily for seven days

DRUG

Normal saline

Normal saline IV three times daily for seven days

Trial Locations (1)

27514

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Rising Tide Foundation

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03263442 - High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter